Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 19/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21936469 | 0.81 | GRIN2B (0.55) | GRIN2BGRIN1KCNH2 | |
| SCHEMBL20939542 | 0.75 | MAP3K14 (0.42) | GRIN2BGRIN1CYP2C9KCNH2CYP2C19 | |
| SCHEMBL24110368 | 0.75 | HTR2C (0.37) | — | |
| SCHEMBL14884748 | 0.75 | KMT2A (0.53) | — | |
| SCHEMBL24110500 | 0.74 | HTR2C (0.36) | — | |
| SCHEMBL22946240 | 0.73 | HDAC3 (0.41) | GRIN2B | |
| SCHEMBL3354522 | 0.72 | GRIN2B (0.45) | GRIN2BGRIN1CYP2C9 | |
| SCHEMBL14487798 | 0.72 | ATM (0.52) | CYP2C9KRASCYP2C19 | |
| SCHEMBL8568248 | 0.71 | KMT2A (0.65) | GRIN2BCYP2C19 | |
| SCHEMBL13537401 | 0.70 | GRIN2B (0.43) | GRIN2BGRIN1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119299-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119299-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, IKBKB | GRIN2B 2899/4885GRIN1 1665/4885CYP2C9 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.